Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial
Related Posts
Chaturvedi R, Gracner T, Tysinger B, Narain K, Goldman D, Sturm R. The Long-term Value of Bariatric Surgery Interventions for American Adults With Type 2 ...
Hu FY, Tabata-Kelly M, Johnston FM, Walling AM, Lindvall C, Bernacki RE, Pusic AL, Cooper Z. Surgeon-reported Factors Influencing Adoption of Quality Standards for Goal-concordant ...
Armstrong AW, McConaha JL. Tapinarof cream 1% once daily for the treatment of adults with mild to severe plaque psoriasis: A novel topical therapy targeting ...